Conjugate Vaccine Market Growth Is Accelerating As Industry Transformation Continues
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Conjugate Vaccine Market Revenue Outlook: What CAGR Is Expected Through 2030?
The conjugate vaccine market has experienced swift expansion over the past several years. Projected to rise from $21.26 billion in 2025 to $23.84 billion in 2026, this growth corresponds to a compound annual growth rate (CAGR) of 12.1%. Historical advancement in this sector has been driven by factors such as immunization campaigns spearheaded by governments, the widespread occurrence of bacterial infections, backing from worldwide health bodies, the established effectiveness of conjugate vaccines, and a growing pediatric demographic.
The conjugate vaccine industry is forecasted to experience significant expansion over the coming years, reaching a valuation of $38.54 billion by 2030 with a compound annual growth rate of 12.8%. Several driving forces are fueling this anticipated growth, including a heightened need for combination vaccines, the broadening of immunization initiatives for adults, greater financial backing for vaccine research and development, an elevated emphasis on combating antimicrobial resistance, and enhancements to cold chain infrastructure. Key developments shaping this period include the broadening of childhood vaccination schedules, a growing preference for multivalent conjugate vaccines, a stronger focus on enduring immune responses, an increase in cooperative ventures between public and private sectors, and progress in carrier protein technologies.
Download A Free Sample Report For Comprehensive Market Insights:
Conjugate Vaccine Market Expansion Supported By Key Demand Factors
The growing prevalence of infectious diseases is anticipated to accelerate the expansion of the conjugate vaccine market. Infectious diseases are illnesses caused by pathogenic microorganisms, including bacteria, viruses, parasites, or fungi, and they can be spread directly or indirectly between people, from animals to humans, or via environmental sources. Conjugate vaccines are essential in preventing infectious diseases caused by specific bacteria, particularly among vulnerable groups like infants and young children. For example, data from the Centers for Disease Control and Prevention, a U.S. government agency, shows that tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, representing a rise of 1,295 cases. Moreover, the incidence rate grew from 2.5 per 100,000 people in 2022 to 2.9 in 2023. Consequently, the increase in infectious disease cases is fueling the growth of the conjugate vaccine market.
Conjugate Vaccine Market Segment Performance And Strategic Opportunities
The conjugate vaccine market covered in this report is segmented –
1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine
2) By Pathogen: Bacterial, Viral
3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid
4) By Patient: Pediatric, Adults
5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users
Conjugate Vaccine Market Growth Trends Influencing Competitive Dynamics
Key industry players within the conjugate vaccine space are prioritizing the advancement of next-generation conjugate vaccines aimed at delivering enhanced coverage against a broader range of pneumococcal serotypes, which helps lessen the health burden among at-risk populations. These innovative vaccines combine bacterial polysaccharides with carrier proteins to stimulate a stronger immune response, especially in infants and those with weakened immune systems, providing superior protection, longer-lasting immunity, and increased efficacy when compared to conventional vaccines. As an example, in August 2025, Pfizer Ltd., a pharmaceutical firm based in India, introduced its new 20-valent Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P., known as PCV20, for adults across India. This launch bolsters its conjugate vaccine product line by enabling more comprehensive defense against pneumococcal illness and contributing to enhanced public health outcomes.
Conjugate Vaccine Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the conjugate vaccine market are Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus
Access The Complete Conjugate Vaccine Market Report:
Conjugate Vaccine Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the global conjugate vaccine market in 2025. The regions covered in the conjugate vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
